Anti-GBM and Adriamycin mice and matched control mice received recombinant FGF23 (1 μg) or vehicle for six days (anti-GBM) or once (Adriamycin model), with dissection 24 h after the last injection. This evidence concerns the gene FGF23 and glioblastoma.